Top Markets
Coin of the day
Anthem Biosciences Ltd. Anthem Biosciences Ltd.

Anthem Biosciences Ltd.

ANTHEM
Rang in Aktien #3292
Anthem Biosciences Ltd. operates as a technology-driven organization... Anthem Biosciences Ltd. operates as a technology-driven organization specializing in contract research, development, and manufacturing (CRDMO). The company's activities are organized into two primary divisions: CRDMO services and the production of Specialty Ingredients. Through its CRDMO segment, Anthem Biosciences offers comprehensive, full-lifecycle support for both novel chemical and biological entities. This support spans the entire development pipeline, from initial target identification and concept generation, through preclinical evaluation, the creation of development batches for all three phases of clinical trials, and ultimately, commercial-scale manufacturing. Their expertise covers a wide array of advanced therapeutic areas, including RNA-based therapies, antibody-drug conjugates, peptides, oligonucleotides, lipids, biologics, and biotherapeutics. They also employ specialized processes such as fermentation, biosynthesis, biotransformation, and flow chemistry. In its Specialty Ingredients division, Anthem Biosciences manufactures and supplies intricate, fermentation-derived active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2. The company's portfolio also encompasses microbial and mammalian biosimilars, a diverse range of probiotics (such as various species of bacillus, lactobacillus, bifidobacterium, streptococcus, and saccharomyces boulardii), and enzymes. Additionally, they produce key peptides like semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide, alongside nutritional actives, vitamin analogues, and other APIs. The company was established in Bengaluru, India, in 2006.
Aktienkurs
$10.18
Marktkapitalisierung
$5.72B
Veränderung (1 Tag)
5.41%
Veränderung (1 Jahr)
6.69%
Land
IN
Handel Anthem Biosciences Ltd. (ANTHEM)

Kategorie

EPS für Anthem Biosciences Ltd. (ANTHEM)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Anthem Biosciences Ltd. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Anthem Biosciences Ltd. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH